Neuroblastoma stands out among pediatric solid tumors because of its relative frequency,
intriguing natural history, prognostic biologic features, and therapeutic challenges. It is the …

Background Despite the development of new treatment options, the prognosis of high‐risk
neuroblastoma patients is still poor; more than half of patients experience disease …

Strategies to treat cancer have focused primarily on the killing of tumor cells. Here, we
describe a differential stress resistance (DSR) method that focuses instead on protecting the …

Background The current standard treatment for patients with high-risk neuroblastoma
includes initial induction chemotherapy with a 21-day interval between induction treatments …

The clinical course of neuroblastoma is more heterogeneous than any other malignant
disease. Most low-risk patients experience regression after limited or even no …

For children with neuroblastoma, the likelihood of cure varies widely according to age at
diagnosis, disease stage, and tumor biology. Treatments are tailored for children with this …

Neuroblastoma, the most common extracranial pediatric solid tumor remains a clinical
enigma with outcomes ranging from cure in> 90% of patients with locoregional tumors with …

Anaplastic lymphoma kinase (ALK) is a receptor tyrosine kinase predominantly expressed in
the developing nervous system. Recently, mutated ALK has been identified as a major …

Purpose Although tumor resection is the mainstay of treatment for localized neuroblastoma,
there are no established guidelines indicating which patients should be operated on …

Purpose This phase II study was conducted to determine the response rate associated with
use of irinotecan and temozolomide for children with relapsed/refractory neuroblastoma …